Murchinson Ltd. Humanigen, Inc Transaction History

Murchinson Ltd.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	BUY	$1.81 - $3.97 $1.36 Million - $2.98 Million	750,000 Added 16.67%	5,250,000 $15.8 Million
Q4 2021 Feb 14, 2022	BUY	$3.66 - $8.22 $12.8 Million - $28.8 Million	3,500,000 Added 350.0%	4,500,000 $16.8 Million
Q3 2021 Nov 15, 2021	SELL	$5.93 - $17.83 $10 Million - $30.1 Million	-1,686,666 Reduced 62.78%	1,000,000 $5.93 Million
Q2 2021 Aug 13, 2021	BUY	$13.54 - $22.74 $36.4 Million - $61.1 Million	2,686,666 New	2,686,666 $46.7 Million

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Murchinson Ltd., based on Form 13F filings with the SEC.

Stay updated on Murchinson Ltd. with notifications on news.